Hydroxychloroquine Retinopathy among Rheumatoid Patients on Hydroxychloroquine (HCQ) Therapy in Malaysia
Main Article Content
Abstract
Objective: To determine the correlation between age, duration and accumulative dose of Hydroxychloroquine (HCQ) usage in HCQ retinopathy.
Methods: This cross-sectional study recruited 130 rheumatoid patients on HCQ therapy. The macula thickness and volume were measured by Spectra-Domain Optical Coherence Tomography (SD-OCT), while visual field examination was performed using Humphrey visual field 24-2 (HVF).
Results: The incidence of HCQ retinopathy observed in rheumatology patients in this study was 1.54% (2 out of 130 patients). No significant difference was noted between mean age of HCQ retinopathy patients (50.5 ± 3.53 years) compared to non-retinopathy patients (42 ± 14 years, P = .39). Similarly, no significant median duration of HCQ intake was observed between retinopathy patients (5475 days, IQR = 0) and non-retinopathy patients (2190 days, IQR = 2555, P = .11). The median daily dose of HCQ did not reveal a significant difference between retinopathy patients (250 mg/d, IQR = 0) and non-retinopathy patients (200 mg/d, IQR = 0, P = .11). Likewise, no significant difference exist in the median accumulative dose of HCQ retinopathy patients (1460 g, IQR = 0), compared to non-retinopathy patients (474.5 g, IQR = 450, P = .1). Overall, the association factor between age, duration and cumulative dose to HCQ retinopathy were not significant (P > .05). However, the average macular thickness and macular volume were significantly lesser in inner macula among retinopathy patients (P < .05).
Conclusion: This study showed no statistically significant relationship was noted between age, duration of HCQ intake, cumulative and the daily dose of HCQ to retinopathy
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Dorner T. Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nat Rev Rheumatol 2010;6:10-1.
Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 2008;47:378-9.
Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Annals of the rheumatic diseases 2007;66(9):1168-72.
Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2016 update. 2017;76(6):960-77.
Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989;27:711-79.
Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17:1158-75.
Sundelin SP, Terman A. Different elements of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 2002;100:481-9.
Hui Jen Ding, Alastair K Denniston, Vijay K. Rao, Caroline Gordon. Hydroxychloroquine related retinopathy. PMID: 26428520, DOI: 10.1093/rheumatology/kev357.
Bernstein HN . Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75:25-34.
Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006;12:294-304.
Rodriguez-Padilla JA, Hedges TR III, Monson B et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 2007;125:775-80.
Stepien KE, Han DP, Schell J et al. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc 2009;107:28-33.
Chen E, Brown DM, Benz MS et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the flying saucer sign). Clin Ophthalmol 2010;4:1151-8.
Puneet argawal. Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness. July 2014. Cutaneous and Ocular Toxicology 34(3). DOI:10.3109/15569527. 2014.938751.
Nuanpan Tangtavorn et al. Incidence of and risk factor for chloroquine and hydroxy-chloroquine retinopathy in Thai rheumatologic patients 2016. Clin Ophthalmol. 2016;10:2179-85.
Doo-ri Eo, Min Gyu Lee; Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci 2017;32(3):522-7.
AAO Quality of Care Secretariat, Hoskins Center for Quality Eye Care Recommendations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy-2016. https://www.aao.org/clinical-statement/revised-recommendations-on-screening-chloroquine-h.
RCOphth guideline: Hydroxychloroquine and Chloroquine Retinopathy: new screening recommendations February 2018. https://www.rcophth.ac.uk/wp-content/uploads/2020/02/HCRRecommendations-on-Monitoring.pdf.
Marmor MF, Kellner U, Lai TY, LyonsJS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-22.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016;123:1386-94.
Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG. Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 2015;122(6):1239-51.e4.
Lee DH, Melles RB, Joe SG, Lee JY. Pericentral Hydroxychloroquine Retinopathy in Korean Patients. Epub 2015. doi:10.1016/j.ophtha.2015.01.014.
Shechtman D, Reynolds SA. How to identidy and screen medication caused retinal toxicity in 2016. https://www.optometricmanagement.com/issues/2016/september-2016/clinical-posterior
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453-60.
Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997;36:599-601.
Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008;23:201-9.
Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62(6):775-84.
Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS. Rheumatol Ther 2015;2(2):183-95.
Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 2015;122:1252-6.
Early Treatment Diabetic Retinopathy Study Research Group. ETDRS Report No. 7: Early Treatment Diabetic Retinopathy Study design and baseline patientcharacteristics. Ophthalmology 1991;98:741-56.